Clinical Trials on Myelodysplastic Syndrome With Ring Sideroblasts in Finland

Total 67 results

medac GmbH

Completed

Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

Finland
Stichting Hemato-Oncologie voor Volwassenen Nederland
Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)

Recruiting

A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2

Australia, Austria, Belgium, Estonia, Finland, France, Germany, Ireland, Lithuania, Luxembourg, Netherlands, Norway, Spain, Sweden, Switzerland
Stichting Hemato-Oncologie voor Volwassenen Nederland
Astellas Pharma Global Development, Inc.; Deutsch-Österreichische Studiengruppe...

Active, not recruiting

A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2

Netherlands, Belgium, Germany, Switzerland, Australia, Finland, Norway, Sweden, Austria, France, Ireland, Lithuania, Luxembourg, Spain
Novartis Pharmaceuticals

Active, not recruiting

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome (MDS)

Spain, Singapore, Australia, Germany, Italy, Finland, United States
Onconova Therapeutics, Inc.

Terminated

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE)

Myelodysplastic Syndrome | MDS | Refractory Anemia With Excess Blasts | RAEB

United States, Spain, Canada, France, Australia, Switzerland, Israel, Japan, Belgium, India, Ireland, United Kingdom, Croatia, Czechia, Poland, Estonia, Germany, Italy, Austria, Hungary, Russian Federation, Sweden
Eisai Inc.

Completed

A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndrome

United States
National Heart, Lung, and Blood Institute (NHLBI)
National Cancer Institute (NCI)

Recruiting

The National Myelodysplastic Syndromes (MDS) Study (MDS)

Myelodysplastic Syndromes (MDS)

United States, Israel
Brown University
Memorial Hospital of Rhode Island; Roger Williams Medical Center

Terminated

Decitabine, Cytarabine, GCSF for Refractory AML/MDS

Leukemia | Myelodysplasia

United States
Dana-Farber Cancer Institute
Charles H. Hood Foundation

Recruiting

Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic Malignancy

Myelodysplastic Syndromes | Leukemia | Myeloproliferative Syndrome

United States
medac GmbH

Completed

Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Germany, Italy, Poland, France, Finland, Hungary
Eisai Inc.

Completed

A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes

Myelodysplastic Syndrome

United States, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Novartis Pharmaceuticals

Completed

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Myelodysplastic Syndromes | Bone Marrow Diseases | Hematologic Diseases | Leukemia | Leukemia, Myeloid | Leukemia, Myeloid, Acute | Preleukemia | Chronic Myelomonocytic Leukemia

United States, France, Australia, Netherlands, Spain, Germany, United Kingdom, Finland
Seagen Inc.

Terminated

Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS

Myelodysplastic Syndrome

United States
Celgene Corporation

Completed

A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Topotecan in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
PureTech

Recruiting

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

MDS | AML, Adult Recurrent

United States
Agios Pharmaceuticals, Inc.

Active, not recruiting

A Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Myelodysplastic Syndromes

Israel, United States, Korea, Republic of, Australia, France, Germany, Spain, United Kingdom, Czechia, Austria, Italy, Greece, Poland
Gilead Sciences

Terminated

Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE)

Myelodysplastic Syndromes

United States, Spain, Belgium, Australia, France, Hong Kong, Hungary, Finland, New Zealand, Germany, Netherlands, United Kingdom, Italy, Switzerland, Portugal, Canada, Austria, Czechia, Norway, Poland, Turkey
Faron Pharmaceuticals Ltd

Recruiting

A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (BEXMAB)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Relapsed/Refractory AML

United States, Finland
Adam Olszewski

Active, not recruiting

Removing Transfusion Dependence as a Barrier to Hospice Enrollment (BRUOG-407)

Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Leukemia | Hematologic Malignancy | Myeloma

United States
Astex Pharmaceuticals, Inc.

Completed

Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

United States, Spain, Korea, Republic of, France, Denmark, Canada, Germany, Italy, Czechia, United Kingdom, Poland, Japan, Sweden, Belgium
National Cancer Institute (NCI)

Active, not recruiting

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myelodysplastic Syndrome/Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Anemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome

United States
Celgene

Completed

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States, Australia, Canada, Czechia, France, Germany, Italy, Korea, Republic of, Mexico, Poland, Sweden, United Kingdom, Belgium, Brazil, Denmark, Finland, Greece, Israel, Netherlands, Norway, Portugal, Spain, Turkey
Incyte Corporation

Recruiting

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms (LIMBER)

Myelofibrosis | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome | Relapsed or Refractory Primary Myelofibrosis | Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis) | ET...

United States, Spain, Japan, Italy, Finland, United Kingdom, Canada
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States, Canada, Puerto Rico, Australia, Netherlands, New Zealand, Switzerland
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (STIMULUS-MDS2)

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

China, Czechia, Japan, Saudi Arabia, Taiwan, Turkey, Germany, Spain, Netherlands, Italy, Singapore, Australia, Austria, France, United Kingdom, Korea, Republic of, Thailand, Israel, Belgium, Canada, Switzerland, Lithuania, Russian Federation and more
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes

Acute Leukemia | Myelodysplasia | Chronic Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Acute Myeloid Leukemia | Down Syndrome | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myeloid Leukemia Associated With Down Syndrome

United States, Canada, Saudi Arabia, Puerto Rico, Australia, New Zealand
Celgene

Recruiting

Connect® Myeloid Disease Registry

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Primary Myelofibrosis

United States, Puerto Rico
Eli Lilly and Company
Loxo Oncology, Inc.

Active, not recruiting

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS) | Myeloproliferative Neoplasms (MPNs)

United States, Spain, Korea, Republic of, France, Taiwan, Australia, Belgium, Singapore, Israel, Canada, Germany, Finland
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

Secondary Acute Myeloid Leukemia | Childhood Acute Erythroleukemia (M6) | Childhood Acute Megakaryocytic Leukemia (M7) | Childhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia With Maturation (M2) | Childhood Acute Myeloblastic... and other conditions

United States, Canada, Australia, Puerto Rico
LLS PedAL Initiative, LLC
National Cancer Institute (NCI); Children's Oncology Group

Recruiting

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Myeloid Leukemia Associated With Down Syndrome | Mixed Phenotype Acute Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy | Myelodysplastic Syndrome Post Cytotoxic Therapy

United States, Canada, Australia, Puerto Rico, New Zealand
National Cancer Institute (NCI)

Active, not recruiting

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

Lynch Syndrome | Colon Mucinous Adenocarcinoma | Colon Signet Ring Cell Adenocarcinoma | Stage IIA Colon Cancer AJCC v7 | Stage IIB Colon Cancer AJCC v7 | Stage IIC Colon Cancer AJCC v7

United States, Canada, Puerto Rico, Peru, South Africa
Universitätsklinikum Hamburg-Eppendorf
Clinical Trial Center North (CTC North GmbH & Co. KG); DKMS Stiftung Leben...

Recruiting

Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia

Myelodysplastic Syndromes | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission

Germany, Spain, Italy, Austria, Czechia, Finland, Russian Federation
European Organisation for Research and Treatment...

Completed

Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count

Lymphoma | Unspecified Childhood Solid Tumor, Protocol Specific | Myelodysplastic Syndromes | Leukemia | Unspecified Adult Solid Tumor, Protocol Specific | Infection | Multiple Myeloma and Plasma Cell Neoplasm | Fever, Sweats, and Hot Flashes | Bone Marrow Suppression

Switzerland, United States, Canada, United Kingdom, Belgium, Israel, Slovakia, Finland, Germany, France, Turkey, Czech Republic, Greece
Solvay Pharmaceuticals

Completed

A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of Fenofibrate, Metformin, Their Combination and Placebo in Patients With Metabolic Syndrome.

Patients With Metabolic Syndrome

Hungary, Canada, Finland, Italy, Netherlands, Norway, Poland, Romania, Sweden
Aronex Pharmaceuticals

Completed

Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Infection | Multiple Myeloma and Plasma Cell Neoplasm

United States
Ardelyx

Recruiting

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

Irritable Bowel Syndrome With Constipation (IBS-C)

United States
National Cancer Institute (NCI)

Completed

Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 | Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 | Adult Acute Myeloid... and other conditions

United States
Ra Pharmaceuticals

Completed

Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, Australia, Canada, Denmark, Finland, Germany, Hungary, New Zealand
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Terminated

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation (LIN-MD-63)

Irritable Bowel Syndrome With Constipation

United States, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Cytogenetic Studies in Acute Leukemia and Multiple Myeloma

Multiple Myeloma | Acute Lymphoblastic Leukemia | Acute Leukemia | Myelodysplastic Syndrome

United States
Allergan

Completed

Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use

Irritable Bowel Syndrome With Diarrhea

United States, Canada
AbbVie
Ironwood Pharmaceuticals, Inc.

Enrolling by invitation

Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

Irritable Bowel Syndrome With Constipation | Functional Constipation

United States, Canada, Israel, Netherlands
Bausch Health Americas, Inc.

Completed

Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study (TARGET3)

Irritable Bowel Syndrome With Diarrhea

United States, United Kingdom, Germany
AbbVie
Ironwood Pharmaceuticals, Inc.

Active, not recruiting

Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) (LINZESS)

Irritable Bowel Syndrome With Constipation | Functional Constipation

United States, Belgium, Bulgaria, Canada, Estonia, Israel, Italy, Netherlands, Poland, Puerto Rico, Spain, Ukraine, United Kingdom, Germany
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation

Irritable Bowel Syndrome With Constipation | Chronic Idiopathic Constipation

United States
Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Completed

An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome With Constipation | Chronic Constipation

United States, Canada

Clinical Trials on Myelodysplastic Syndrome With Ring Sideroblasts in Finland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations